Skip to main content
NACFC 2024 Main banner
Icon Legend
This session is not in your schedule.
This session is in your schedule. Click again to remove it.
Presentation Icons
Livestreamed Session
Livestreamed Session
Ticketed Session
Ticketed Session
Recorded Session
Recorded Session
Back

CLIN
Thematic Poster Session

TPS03--Biomarkers of Infection & Inflammation

Thursday, September 26, 2024
2:30 PM – 4:00 PM ET
Location:Theater A (Exhibit & Poster Hall)

The session consists of two main parts: (1) poster viewing followed by a (2) moderated discussion. It is designed to engage the authors and the audience in a discussion that ties together ideas from multiple posters in the session.

This session will highlight and discuss a number of novel biomarkers of infection and inflammation, their potential role in future CF mechanistic clinical research studies and clinical trials, and their applicability to disease monitoring in clinical practice. Attendees will gain a greater insight into hallmark manifestations of CF lung disease including infection and inflammation.

Learning Objectives:

  • Identify novel biomarkers that can advance our understanding of hallmark manifestations of CF lung disease including infection and inflammation.
  • Investigate various biospecimens including breath, sputum, bronchoalveolar lavage, and blood that can serve as sources of novel biomarkers.
  • Define the potential role of biomarkers in future CF mechanistic clinical research studies and clinical trials.

Presentations:

  • 2:30 PM – 4:00 PM ET
    TPS03.1- Evidence for early reflux/aspiration as a trigger for the vicious cycle of CF airways disease that leads to bronchiectasis.

    Speaker: Charles R. Esther, Jr., MD, PhD – UNC

  • 2:30 PM – 4:00 PM ET
    TPS03.2- Airway and systemic markers of inflammation associated with cystic fibrosis pulmonary exacerbation outcomes

    Speaker: Valerie Waters, Toronto, Canada – The Hospital for Sick Children (SickKids)

  • 2:30 PM – 4:00 PM ET
    TPS03.3- The Stockholm Elexacaftor/Tezacaftor/Ivacaftor Task Force Study: Cohort description and identification of subgroups

    Speaker: Terezia Pincikova, MD, PhD (she/her/hers) – Stockholm CF Center, Division of Pediatrics, Department of Clinical Science, Intervention and Technology, Karolinska Institutet, Stockholm, Sweden

  • 2:30 PM – 4:00 PM ET
    TPS03.4- Plasma proteomics identifies changes in disease-associated pathways in subjects with CF bronchiectasis following Elexacaftor/Tezacaftor/Ivacaftor Initiation

    Speaker: Emily J. Skala, BS – Cincinnati Children's Hospital

  • 2:30 PM – 4:00 PM ET
    TPS03.5- Specific Pseudomonas aeruginosa IgG levels before and after elexacaftor/tezacaftor/ivacaftor treatment

    Speaker: Thomas Bryrup, MD (he/him/his) – Department of Infectious Diseases, Rigshospitalet

  • 2:30 PM – 4:00 PM ET
    TPS03.6- Siderophores as biomarkers for Pseudomonas aeruginosa infection in cystic fibrosis

    Speaker: Pavel Drevinek, MD PhD (he/him/his) – Second Faculty of Medicine Charles University and Motol University Hospital

  • 2:30 PM – 4:00 PM ET
    TPS03.7- Detection of Nontuberculous Mycobacteria Disease Using Volatile Biomarkers

    Speaker: Antao Gao, MS – University of British Columbia

  • 2:30 PM – 4:00 PM ET
    TPS03.8- Detection of Nontuberculous Mycobacteria Abscessus and Phage Treatment Response Using Volatile Biomarkers

    Speaker: Antao Gao, MS – University of British Columbia

  • 2:30 PM – 4:00 PM ET
    TPS03.9- Longitudinal profiles of human breath reveal potential biomarkers for detecting and monitoring infections in cystic fibrosis during ivacaftor and antibiotic therapies

    Speaker: Josephine Ackah-Cudjoe, MSc (she/her/hers) – University of British Columbia

  • 2:30 PM – 4:00 PM ET
    TPS03.10- Development of a co-culture model for secondary screening of candidate anti-microbial compounds targeting persistent lung infections in cystic fibrosis.

    Speaker: Hannah Donnelly, PhD (she/her/hers) – University of Dundee